Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

(2012) Sreeneeranj Kasichayanula et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Diagnosis and Classification of Diabetes Mellitus

(2012)   DIABETES CARE

Energy loss via urine and faeces - a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight

(2012) R. Elvert et al.   DIABETES OBESITY & METABOLISM

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

(2012) David G Parkes et al.   Expert Opinion on Drug Discovery

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

(2012) Jean Whaley et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

(2010) Que Liu et al.   Cardiovascular Diabetology

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE